Get the Stockscreener App
13.76
2.99%
0.40
Pre-market:
13.70
-0.06
-0.44%
Arvinas Inc stock is traded at $13.76, with a volume of 754.52K.
It is up +2.99% in the last 24 hours and up +2.76% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$13.36
Open:
$13.5
24h Volume:
754.52K
Relative Volume:
0.88
Market Cap:
$883.73M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-2.9465
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+3.50%
1M Performance:
+2.76%
6M Performance:
+80.81%
1Y Performance:
-16.71%
1-Day Range:
$13.29
$13.93
1-Week Range:
$12.61
$13.93
52-Week Range:
$5.90
$18.93
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
13.76 | 858.04M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - Yahoo Finance
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead - TradingView
ARVN: Multiple phase 1 programs advance with key data updates expected for LRRK2, BCL6, and KRAS - TradingView
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares - MarketBeat
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Insider Monkey
Arvinas (NASDAQ:ARVN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
TD Cowen Health Care Conference - marketscreener.com
Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley - The Globe and Mail
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the 6.50% Upside Potential Amidst Clinical Innovations - DirectorsTalk Interviews
HC Wainwright Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas Holding Company (ARVN) Receives a Buy from Wells Fargo - The Globe and Mail
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus - MSN
Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN) - The Globe and Mail
New CEO at local biotech firm is leading shift to early-stage drugs - Yale Daily News
Barclays Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas CSO Cacace sells $43,885 in stock to cover tax obligations - Investing.com Australia
Arvinas chief accounting officer Loomis sells $13k in stock By Investing.com - Investing.com South Africa
Teel Randy, president and CEO of Arvinas, sells $58k in stock By Investing.com - Investing.com Australia
Teel Randy, president and CEO of Arvinas, sells $58k in stock - Investing.com Canada
Arvinas chief accounting officer Loomis sells $13k in stock - Investing.com Australia
Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,108 Shares - MarketBeat
Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,786 Shares - MarketBeat
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
5 Analysts Assess Arvinas: What You Need To Know - Benzinga
Arvinas (NASDAQ:ARVN) Trading Up 9%Still a Buy? - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler Raises Price Target on Arvinas (ARVN) to $20.00 | - GuruFocus
ARVN: Evercore ISI Raises Price Target to $19, Maintains Outperf - GuruFocus
Arvinas (ARVN): Wedbush Maintains Neutral Rating and Raises Pric - GuruFocus
Arvinas, Inc. (NASDAQ:ARVN) Q4 2025 Earnings Call Transcript - Insider Monkey
Arvinas (ARVN) Q4 Loss Of US$67.4 Million Reinforces Profitability Concerns - Sahm
Arvinas earnings missed by $0.59, revenue fell short of estimates - Investing.com Australia
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Arvinas (ARVN) Reports Significant Revenue Decline in Q4 - GuruFocus
Wedbush raises Arvinas stock price target to $11 on pipeline progress By Investing.com - Investing.com South Africa
Wedbush Maintains Neutral on Arvinas, Inc. (ARVN) Feb 24, 2026 - Meyka
ARVINAS, INC. SEC 10-K Report - TradingView
Wedbush raises Arvinas stock price target to $11 on pipeline progress - Investing.com Australia
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... By GuruFocus - Investing.com Canada
Arvinas (ARVN) Projects Financial Stability into Late 2028 - GuruFocus
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating - GuruFocus
Wedbush Lifts Price Target on Arvinas to $11 From $9, Keeps Neutral Rating - marketscreener.com
Arvinas (ARVN) Q4 2025 Earnings Call Transcript - AOL.com
Arvinas Q4 2025 Earnings Call Transcript - MarketBeat
Arvinas, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ARVN: Strong cash position and pipeline progress set up multiple clinical milestones for 2026 - TradingView
Arvinas Q4 Earnings Call Highlights - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap Down After Earnings Miss - MarketBeat
Earnings call transcript: Arvinas Inc. Q4 2025 results miss expectations, stock dips - Investing.com Nigeria
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Misses Expectations By $0.55 EPS - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):